ABSTRACT
Iran has increased its CO2 emissions significantly during the past few decades. The household sector in Iran contributes one of the largest sectors of CO2 emissions. Despite this significant contribution, the existing policies have predominantly concentrated on large-scale initiatives while overlooking the regional role in shaping and implementing these plans. Therefore, this study investigates the relationship between CO2 emissions and the efficient factors in three major groups including energy, climate, and household socio-economic factors. This study aims to address regional carbon emissions and develop CO2 reduction policies tailored to each region's specific circumstances. It focuses on planning strategies at the regional level to effectively tackle CO2 emissions. Household panel data of 28 provinces of Iran are employed by using both static and dynamic panel models for the years 2001 to 2019. Static estimation includes Fixed Effect (FE), Random Effect (RE) and pooled Partial least squares (PLS), Dynamic estimation includes difference Generalized Method of Moments (GMM) and system Generalized Method of Moments (GMM). The empirical result of the static method showed positive dependence of household CO2 emissions on Heating Degree Days (HDD), Cooling Degree Days (CDD), precipitation level, oil consumption, gas consumption, household income, size of household, and also building stocks. In more detail, educational rate, dummy variable (removal of energy subsidy), and oil price reveal the greatest negative impact on the emissions with elasticities of - 0.428, - 0.31, and - 0.15; It represents 1% increase causes - 0.428, - 0.31, - 0.15, decrease CO2 emissions, respectively. however, household size, gas consumption, and oil consumption show the most significant positive effects on CO2 emissions with 1 percent increase causes CO2 emissions increases by 0.1, 0.044, and 0.026, respectively. Regarding the impact of climate factors, a 1% increase in Heating Degree Days, Cooling Degree Days, and precipitation level causes CO2 emissions increase by 0.024%, 0.004%, and 0.011% respectively, due to an increase in fossil energy demand. Results of the dynamic method of the system Generalized Method of Moments are similar to the static estimation results, except for that household size and urbanization are not significant. Also, removing the energy subsidy for fossil fuels due to substantial subsidy in fossil fuels in Iran or implementing a re-pricing energy policy can be a beneficial way to control carbon emissions from households within the provinces of the country. However, it is important to consider that this shift could potentially transfer subsidies to investments in the private sector for renewable energies.
ABSTRACT
UNLABELLED: The balance between the pain relief provided by opioid analgesics and the side effects caused by such agents is of particular significance to patients who take opioids for the long-term relief of non-cancer pain. The spectrum of signs and symptoms affecting the gastrointestinal (GI) tract associated with opioid use is known as opioid-induced bowel dysfunction. Alvimopan is an orally administered, systemically available, peripherally acting mu-opioid receptor (PAM-OR) antagonist, approved in the US for the management of postoperative ileus in patients undergoing bowel resection (short-term, in-hospital use only). Alvimopan was under clinical development for long-term treatment of opioid-induced constipation (OIC) but this program has been discontinued. This double-blind, placebo-controlled trial, part of the former OIC development program, enrolled patients (N = 485) receiving opioids for non-cancer pain. Patients were randomized to receive alvimopan .5 mg once daily, alvimopan .5 mg twice daily, or placebo, for 12 weeks. The primary efficacy endpoint was the proportion of patients who experienced ≥ 3 spontaneous bowel movements (SBMs; bowel movements with no laxative use in the previous 24 hours) per week over the treatment period, and an average increase from baseline of ≥ 1 SBM per week. There were greater proportions of SBM responders in both alvimopan treatment groups (63% in both groups) compared with placebo (56%), although these differences were not statistically significant. Secondary efficacy analyses indicated that alvimopan was numerically superior to placebo in improving opioid-induced bowel dysfunction symptoms and patients' global assessment of opioid-induced bowel dysfunction, and reduced the requirement for rescue laxatives. Active treatment was well tolerated and alvimopan did not antagonize opioid analgesia. PERSPECTIVE: Although the primary endpoint was not met in this study, the magnitude of alvimopan-induced improvements versus baseline, together with previous study results, suggest that a PAM-OR antagonist has the potential to improve OIC.
